Cao Pikun, Wei Zhigang, Xue Guoliang, Wang Nan, Li Zhichao, Hu Yanting, Wang Gang, Ye Xin
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China.
Quant Imaging Med Surg. 2024 Oct 1;14(10):7218-7228. doi: 10.21037/qims-24-906. Epub 2024 Sep 11.
This was a retrospective, large-sample, case-control study assessing the complications associated with synchronous microwave ablation (MWA) and biopsy for pulmonary sub-solid nodules or ground-glass nodules (GGNs) versus MWA alone. We aimed to verify the safety of synchronous MWA and biopsy for treating GGNs.
From May 2020 to December 2021, 326 patients with GGNs were enrolled. Among them, 164 patients underwent MWA alone (group A) and 162 patients underwent synchronous MWA and biopsy (group B). We assessed the complications, technical success, and positivity rate of the biopsy.
The major complications were similar between the two groups, and included pneumothorax (group A group B, 19.5% 13.6%; P=0.150), hemothorax (0.6% 1.2%; P=1.000), pleural effusion (1.2% 0.6%; P=1.000), and pulmonary infection (4.9% 6.2%; P=0.609). No massive hemoptysis, bronchopleural fistula, or air embolism developed. Minor complications including intrapulmonary hemorrhage (group A group B, 28.7% 62.3%, P<0.001), mild pneumothorax (20.7% 29.6%, P=0.587), mild ipsilateral pleural effusion (30.5% 27.8%, P=0.590), mild bilateral pleural effusion (16.5% 22.2%, P=0.188), and subcutaneous emphysema (4.3% 5.6%, P=0.498) were observed. The side effects, including pain, cough, post-ablation syndrome, and post-ablation chronic pain syndrome, were similar between the two groups. The positive diagnosis rate of biopsy in group B was 88.3%.
Compared with MWA alone, synchronous MWA and biopsy did not increase the risk of major complications. Although some minor complications developed, synchronous MWA and biopsy is safe for treating pulmonary GGNs.
这是一项回顾性、大样本病例对照研究,旨在评估同步微波消融(MWA)联合活检治疗肺亚实性结节或磨玻璃结节(GGN)与单纯MWA相比的并发症情况。我们旨在验证同步MWA联合活检治疗GGN的安全性。
2020年5月至2021年12月,纳入326例GGN患者。其中,164例患者接受单纯MWA治疗(A组),162例患者接受同步MWA联合活检治疗(B组)。我们评估了并发症、技术成功率和活检阳性率。
两组主要并发症相似,包括气胸(A组19.5%,B组13.6%;P = 0.150)、血胸(0.6% 对1.2%;P = 1.000)、胸腔积液(1.2% 对0.6%;P = 1.000)和肺部感染(4.9% 对6.2%;P = 0.609)。未发生大量咯血、支气管胸膜瘘或空气栓塞。观察到的次要并发症包括肺内出血(A组28.7%,B组62.3%,P < 0.001)、轻度气胸(20.7% 对29.6%,P = 0.587)、轻度同侧胸腔积液(30.5% 对27.8%,P = 0.590)、轻度双侧胸腔积液(16.5% 对22.2%,P = 0.188)和皮下气肿(4.3% 对5.6%,P = 0.498)。两组的副作用,包括疼痛、咳嗽、消融后综合征和消融后慢性疼痛综合征相似。B组活检阳性诊断率为88.3%。
与单纯MWA相比,同步MWA联合活检并未增加主要并发症的风险。尽管出现了一些次要并发症,但同步MWA联合活检治疗肺GGN是安全的。